TX-KAHUNA-WORKFORCE
Kahuna Workforce Solutions, the leading provider of skills and competency management software, has formed a strategic partnership with Norwegian operating services provider PXO AS to accelerate workforce competency in Norway’s booming energy sector, which is a significant stabilizer of the world’s oil and gas supply, particularly in meeting European demand.
The two companies, both of which already have established customers in Norway, have identified opportunities to jointly support the region’s growing demand for technically skilled professionals in the energy sector. The partnership specifically aims to improve operations readiness and assurance by combining Kahuna’s dynamic, digitized competency management platform with PXO’s extensive technical and field experience in a variety of operating production facilities offshore and onshore.
“PXO represents everything we look for in a partner as we strive to ensure successful and rapid adoption of competency-based training and development programs,” said Jai Shah, CEO of Kahuna Workforce Solutions. “As a company that works with many of the same customers as PXO, we’ve seen their expertise firsthand. It is clear they are the right partner to help us not only address the current needs of the energy industry but also pioneer innovative solutions that will shape the future of competency readiness and assurance in Norway.”
The collaboration comes at a critical time for the region, as Norway expects to draw nearly $22 billion in investments from oil and gas companies in 2024. The country is also leading the world toward cleaner energy solutions. Kahuna and PXO’s partnership will help Norwegian energy companies navigate this transition in a variety of ways, including streamlining skills validation and aligning operational standards with expanding ESG initiatives and emerging technologies.
“Just as we serve as a bridge between project and operation phases, Kahuna equips enterprises with validated competency data,” said Leif Olav Moe, CEO of PXO. “By uniting our technical and operational expertise with their cutting-edge competency management solutions, we are delivering a unique solution unlike anything the market has yet to provide—signifying our commitment to building a more skilled and competitive workforce to ascertain safer and more efficient operations.”
"At Kahuna, we are empowering organizations throughout the energy value chain by providing validated competency data and unique insights. This enables a deep understanding of workforce capabilities for seamless operational execution, in addition to aligning talent supply with demand and maximizing the return on investment in technical training,” Shah said. “When you combine our capabilities with PXO’s extensive experience in supporting operations with strategic training and competency services, there is no other competency management solution that comes close to building a skilled, safe, compliant, and competitive workforce.”
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
About PXO
PXO's services are mainly within the petroleum industry with field operating companies as clients, however, the services are also applied within other industry segments, such as shipping, renewable energy and aquaculture.
PXO increases awareness of safety barriers and their functions to improve efficiency and safety in field operations. Exposed to increasingly demanding requirements from authorities, clients, suppliers, and other stakeholders as regards knowledge and experience require systematic and targeted competence development of operations personnel in particular, extending from planning through construction & start-up and into regular operations. PXO ensures that prevailing competence requirements are met and followed up through various measures:
- Systematization of specific competence requirements
- Development of model-based interactive management tools (portal solutions)
- Harmonization of job descriptions and work processes
- Development and execution of training plans through interactive computer based training and practical On the Job Training (OJT) programmes.
PXO is focused on the interaction between people, organization and technology as a means to optimize, integrate and align work processes and technical equipment for robust and safe overall solutions.
For more information, visit https://www.pxo.no/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206626623/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom